SREBF1 and metabolic dysfunction-associated steatohepatitis: Results showed that the NASH group exhibited elevated mRNA expression of Srebf1 and Pparg by 1.33-fold and 2.48-fold, respectively, with Pparg showing a significant increase (p < 0.001 versus control).